MorphoSys

Daiichi snares Germany's U3 in $235M acquisition

Wed, 21 May 2008 06:59:58 -0400

Daiichi Sankyo is buying Germany's U3 Pharma for $235 million in cash. The Japanese pharma company gains a developer that's been winning kudos for its work developing antibodies to fight a variety of cancers. And its lead program is bound for the clinic later this year.

Edmond de Rothschild Investment Partners has been backing U3 since 2003, when it was won over by the research work of Axel Ullrich of the Max Planck Institute. Ullrich's research has helped create such cancer blockbusters as Herceptin and Sutent.

"Our acquisition of U3 Pharma is an ideal strategic fit for our oncology portfolio," said Takashi Shoda, president and CEO of Daiichi Sankyo. "We currently have three human monoclonal antibodies in development. Additionally, in March, 2008, we announced that we were expanding our joint research venture with another German company, MorphoSys, for its advanced Human Combinatorial Antibody Library and its phage display technologies."

- check out the press release
- read the AFX report

ALSO NOTED: Salix gets approvable letter; Intermune drug hits the fast track; and much more...

Mon, 19 May 2008 06:59:50 -0400

> Should Fred Hassan (photo) give back his bonus? That's what Forbes is asking this week, saying that the Schering-Plough CEO's 2007 compensation package was probably artificially inflated by the fact that sales-damaging study results were held back until early January 2008. Report

> Salix says it has received an approvable letter from the FDA for balsalazide tablet studied as a treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older. The company says it should be able to provide a complete response to the letter in a matter of days. Release

> The FDA has put Intermune's drug pirfenidone--for idiopathic pulmonary fibrosis--on the regulatory fast track. Story

> Holmes Biopharma announced that its clinical research operations in Omaha, Nebraska have been disrupted due to a working capital deficiency. Release

> MorphoSys has extended its research contract with Schering-Plough by a year. Report

> Biophage Pharma has sold the assets of its Immunotox Labs Division to Validapro BioSciences Inc. for $400,000 in cash and the assumption by Validapro Biosciences of certain liabilities. Release

> In a deal with the U.S. Department of Justice, the Canadian drugmaker agreed to pay almost $25 million to settle claims that it paid docs and their office managers to get patients onto its Cardizem heart drug. Report

> The FDA is warning doctors again that organ-transplant drugs CellCept (from Roche) and Myfortic (Novartis) have been linked to miscarriages and birth defects when taken by pregnant women. Report

And Finally... A simple gene test may soon be available that will eliminate up to half of the potential patients for the therapy. Report

ALSO NOTED: Endo buys Novartis' Voltaren; Microbia, Forest produce positive Phase III data; and much more...

Wed, 05 Mar 2008 06:59:50 -0500

> Endo Pharmaceutical is buying Novartis' Voltaren gel for $85 million upfront and a one-time sales milestone of $25 million. Release

> Researchers for Microbia and Forest Laboratories have produced positive Phase II data from two studies of linaclotide in patients with chronic constipation as well as patients with irritable bowel syndrome with constipation. Release

> MorphoSys has inked a deal to supply genetically engineered antibodies to Spain's Proteomika SL for use in research into diagnostics and novel treatments. Release

> After some arm-twisting from the FDA, Roche has added stronger warnings to its Tamiflu label. Report

> A new study shows that costlier drugs may work better. Report

> Another prominent South Korean biomedical researcher stands accused of faking data that appeared in prestigious scientific journals. Report

> Leaders in the nanotech field have been beating a path to Congress, asking lawmakers to significantly boost federal support of research into molecular-level advances. Report

> Hormones produced by the heart could play a remarkable role in controlling and perhaps even curing cancer. Report

> Forget those studies of long-lived Italian shepherds and Greek fishermen. It's not fresh air or exercise or a simple whole-foods diet that causes certain people to live past 100, a new study shows. Instead, it's a set of genetic mutations thought to interfere with normal cell growth and thus slow aging. Report

And Finally... Several of the world's top biomedical research institutes--including a couple run by biopharma giants--have made this year's list of the best places for postdocs to work. Report

ALSO NOTED: Cephalon, NitroMed make cuts jobs; IonGate gains funds; and much more...

Wed, 16 Jan 2008 06:59:50 -0500

> Cephalon is cutting jobs as it restructures, shifting manufacturing work from Minnesota to Salt Lake City and relocating some R&D work from Salt Lake City to Minnesota. Report

> NitroMed is in trouble. The company is not only shutting down its sales force and laying off 70 of the 90 people work work there, but asking the investment bank Cowen & Co. to advise it on "strategic alternatives." Report

> IonGate Biosciences has garnered €4.6 million in its third venture round. Heidelberg Innovation and KfW (Kreditanstalt für Wiederaufbau) led the round. Release

> Nycomed is looking for partners in the U.S. following the FDA's approval of Alvesco, its asthma inhaler therapy. Release

> ExonHit Therapeutics has created two commercial business units: the Molecular Diagnostics and Genomic Services Unit and the Therapeutics Unit. Release

> Germany's MorphoSys has acquired patent rights on protein inhibitors from the University of Melbourne, advancing its work on an experimental rheumatoid arthritis therapy. Release

> Teva Specialty Pharmaceuticals and UCB have signed a commercialization pact on Teva's respiratory products. Release

> MAP Pharmaceuticals and the FDA have reached a protocol agreement for a clinical study of MAP0004, a migraine therapy. Release

> Scientists in Singapore are advocating new rules that would permit researchers to splice human DNA into animals to further stem cell research. Report

> Research groups were left shaking their heads in disappointment over news that next year's budget for the National Institutes of Health--the largest single supporter of biomedical research in the U.S.--will boost spending by a meager 0.5 percent. Report

> Science has taken another big step in the direction of building new body organs from stem cells. A team of scientists have constructed a new rat heart, injecting cells from newborn rodents onto a scaffold of valves that were left intact after dead heart cells were removed. Report

> The European Commission has launched a pharma antitrust probe, looking for evidence that industrial hijinks are keeping new products off the market and delaying cheaper generics. Report

> It didn't take long for allegations of improper marketing from two Amgen sales reps to attract the attention of government watchdogs. First, the New Jersey Attorney General formed a task force to investigate pharma-doctor interaction. And now, perpetual pharma bloodhound Sen. Charles Grassley (R-IA) is sniffing around the cases. Report

And Finally... A new genetic test kit is being marketed that will give men an advance warning on going bald. Report